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ABSTRACT  
Objective: Telmisartan (TEL), an angiotensin type 1 receptor blocker, exerts neuroprotection in MPTP induced Parkinson’s disease. The present 
study was aimed to investigate its effects on oxidative stress markers–inducible nitric oxide synthase (iNOS), nitric oxide (NO) and reduced 
glutathione (GSH) content in C57BL/6J mice brain.  
Methods: Young healthy male C57BL/6J mice were injected intraperitoneally with MPTP at 80 mg/kg in two divided doses (2 x 40 mg/kg at 16h 
interval). TEL was administered one hour prior to first MPTP intoxication and thereafter once in two consecutive days. The animals were sacrificed 
48 h after first MPTP injection and brains were collected for further analysis. 
Results: TEL administration increased GSH content and decreased iNOS expression and NO level in MPTP intoxicated mice brains. Histopathological 
evaluation revealed that TEL decreased the cytoplasmic vacuolation and nuclear pigmentation in striatal and substantial nigral regions of MPTP 
intoxicated mice brain. The neuroprotective effect of TEL was further evidenced with increased neuronal nuclei (NeuN) immune fluorescence in 
MPTP mice brains. 
Conclusion: The present study showed that TEL exerts neuroprotection by suppressing nitric oxide induced oxidative stress and the dopaminergic 
degeneration. The above finding suggests that TEL may act as a potential target in the management of PD.  
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INTRODUCTION 
Oxidative stress and neuroinflammation are the two major 
hallmarks in various neurodegenerative disorders including 
Parkinson’s disease (PD). Increased inducible nitric oxide synthase 
(iNOS) expression and nitric oxide (NO) levels were observed in PD 
postmortem brains [1]. The involvement of NO in the pathogenesis 
of PD was also demonstrated in experimental animal models [2]. In 
addition, studies have shown that increased iNOS expressions and 
NO levels in striatal (ST) or substantia nigral (SNPc) regions 
following MPTP administration in C57BL/6J mice [3-6]. 
iNOS, induced by pro-inflammatory cytokines (TNF-α, IL-1β, and 
IFN-γ) produces highly toxic molecules such as NO [7-9] and 
reactive oxygen species (ROS) [10]. Under pathological conditions, 
NO contributes to overproduction of highly toxic intermediates 
such as peroxynitrite, nitrogen dioxide, carbonate and hydroxyl 
radicals [11, 12].  
Another major event of NO neurotoxicity is through s-nitrosylation by 
modifying the cysteine residues, precursor for glutathione synthesis to 
nitrosothiols [13, 14]. Overproduction of NO ultimately results in loss of 
an electron transport chain by complex I inhibition, leading to 
mitochondrial dysfunction and intense ROS generation [15]. Decreased 
glutathione (GSH) level, most abundant antioxidant thiol residue 
involved in the detoxification of peroxides was observed in PD brain 
regions [16].  
Increased production of ROS and decreased antioxidant capacity 
compromises essential cellular function. Increased attention has 
been paid recently in ameliorating PD through the renin angiotensin 
system (RAS) modulators. Previous studies confirmed that 
telmisartan (TEL), an angiotensin II type 1 receptor (AT1R) 
antagonist exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mice model [17, 18]. The present study 
demonstrates the role of TEL on oxidative stress markers in MPTP 
intoxicated PD mice model. 
MATERIALS AND METHODS 
Chemicals and reagents 
TEL was obtained as the gift from Sun Pharmaceutical Pvt. Ltd., 
Mumbai, India. MPTP and TRIzol reagent were purchased from 
Sigma Aldrich, USA. Mouse anti-neuronal nuclei (NeuN) and 
Tetramethylrhodamine (TRITC) conjugated goat anti-mouse IgG 
were obtained from Millipore, USA. PCR master cycler gradient was 
purchased from Genet Bio, Korea. 5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate for alkaline 
phosphatase kit was obtained from Ge Nei™, Mumbai. Carboxy 
methyl cellulose (CMC) was obtained from Himedia, Mumbai. Unless 
mentioned, all other chemicals and reagents were of analytical 
grade. 
Animal husbandry  
Male C57BL/6J mice (18-22 g b. wt) obtained from the Central 
Animal facility, Sri Ramachandra University, Chennai was used for 
the study. Animals were housed in groups (5 animals/cage) in 
polypropylene cages in a well-ventilated room (air cycles: 12-15/h; 
recycle ratio: 70:30) under an ambient temperature of 22±3 °C and 
40–65% relative humidity, with a 12-h light/dark artificial light 
cycle. They were provided with rodent feed (M/s. Provimi Animal 
Nutrition India Pvt. Ltd, India) and purified water ad libitum. 
Animals were acclimatized for 7 days to the laboratory conditions. 
Guidelines of “Guide for the Care and Use of Laboratory Animals” 
(Institute of Laboratory Animal Resources, National Academic Press 
1996; NIH publication number #85-23, revised 1996) were strictly 
followed throughout the study. Institutional Animal Ethics 
Committee (IAEC), Sri Ramachandra University, Chennai, India 
approved the study (IAEC/XXII/SRU/159/2011). 
Experimental design  
Animals were divided into five groups with 10 in each group. Group I 
received vehicle (0.5% CMC), Group II received vehicle+MPTP, 
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Group III and IV received TEL at 3 and 10 mg/kg, p. o, respectively 
[Two dose regimens were selected to investigate the dose 
dependent response]+MPTP, Group V received TEL at 10 mg/kg, p. o 
alone. MPTP was injected intraperitoneally at 80 mg/kg b. wt in two 
divided doses (2 x 40 mg/kg at 16 h apart). Vehicle or TEL was 
administered one hour before the first injection of MPTP and 
thereafter once a day for two consecutive days. Animals were 
euthanized using CO2 exposure and brain was collected for analysis, 
48 hours after the first MPTP injection [19].  
Reverse transcriptase–polymerase chain reaction (RT-PCR) 
analysis 
RT-PCR was performed according to the manufacturer’s instructions 
using one step PCR kit method to determine the level of mRNA 
expression of iNOS. Briefly, total RNA was extracted from ST and 
SNpc brain regions using TRIzol Reagent (Sigma, USA).  
After homogenization, the tubes were incubated for 10 min and 
centrifuged. Chloroform was added to the supernatant, allowed to 
incubate for 5 min at room temperature and centrifuged at 12000 
rcf. Then, isopropyl alcohol was added to precipitate the total RNA 
and centrifuged for 15 min, following the incubation period of 10 
min. The supernatant was decanted carefully; the pellet was washed 
three times with 75% ethanol, centrifuged and the pellet was 
allowed to air dry. The pellet was re suspended in RNase free water 
and stored in -80 °C until use. The isolated RNA was allowed to 
undergo reverse transcription and polymerization reaction to get 
cDNA using PCR master cycler gradient (Genet Bio, Korea). The gene 
expression was analyzed using the bands formed in agarose gel 
electrophoresis, captured using Gel documentation unit (Vilber 
Laumar, Germany) and quantified by Bio ID software.  
Primers sequence used were as follows, β-actin: sense, 5’-CCT CTA 
TGC CAA CAC AGT GC-3’; antisense, 5’-GTA CTC CTG CTT GCT GAT 
CC-3’ and iNOS: sense, 5’-GTG TTC CAC CAG GAG ATG TTG-3’; 
antisense 5’-CTC CTG CCC ACT GAG TTC GTC-3’. 
Reduced glutathione (GSH) content 
GSH was estimated in brain SNpc and ST regions according to the 
method of Moren et al. [20]. 0.25 ml of 10% tissue homogenate was 
mixed with the equal volume of ice cold 5% TCA. The precipitate 
was removed by centrifugation at 4000 rpm for 10 min. To 0.1 ml 
supernatant, 0.25 ml of 0.2 M phosphate buffer (pH 8.0) and 0.5 ml 
of 5,5'-dithiobis-(2-nitrobenzoic acid) were added and mixed well. 
The intensity of colour developed was measured at 412 nm using UV 
spectrophotometer (Thermo Fisher Scientific, USA). The values were 
expressed in µM/mg protein. 
Total protein 
Total protein in SNpc and ST brain regions was estimated using 
Bradford reagent [21]. 
Nitrite levels 
Nitric oxide (NO), which interacts with oxygen to produce nitrite, 
was estimated using Griess reagent [22]. 0.2 ml of 10% tissue 
homogenate was mixed with 1.8 ml of saline and 0.4 ml of 5-
sulfosalicylic acid for protein precipitation. The precipitate was 
removed by centrifugation at 4000 rpm for 10 min. To 1 ml of 
supernatant, 2 ml griess reagent was added and mixed well.  
The mixture was allowed to stand for 20 min under dark condition 
and the intensity of chromogen was read at 540 nm using UV 
spectrophotometer (Thermo Fisher Scientific, USA). The values were 
expressed in mM/mg tissue. 
Histopathology  
5 µM-thick paraffin sections through matched coronal levels of the 
SNpc and ST were stained with cresyl violet for histopathological 
evaluation and scoring [23] under light microscopy at x400 
magnification (Motic DMB1–2MP, China). The number of nissl 
positive cells in the striatum and substantia nigra were counted with 
image analysis software (Motic DMB1–2MP, China). Percentage nissl 
positive cells were calculated as: (Number of positive cells/mm2)/ 
(Total number of cells/mm2) X 100. 
Immunoflourescence  
5 µM-thick paraffin sections through matched coronal levels of the 
SNpc and ST were processed as described above and non-specific 
binding was blocked by 1 h incubation in 1.5% BSA. Sections were 
incubated with primary antibody, mouse anti-NeuN (1:100) for one 
hour and then subsequently incubated with secondary antibody, 
TRITC conjugated goat anti-mouse IgG (1:20) for half an hour at 
room temperature. The number of positive cells in SNpc and ST was 
counted under x400 magnification with image analysis software 
(Motic DMB1–2MP, China). Percentage immunopositive cells were 
calculated as: (Number of immunopositive cells/mm2)/(Total 
number of cells/mm2) X 100. 
Data analysis 
Data were expressed as mean±Standard error of the mean (SEM). 
Mean differences between groups were analysed by one way ANOVA 
followed by Tukey’s multiple comparison as posthoc test using 
Graphpad Prism 5.0 (San Diego, USA) software. p value ≤ 0.05 was 
considered significant. 
RESULTS 
TEL down-regulated iNOS expression in MPTP intoxicated mice 
brain 
SNpc and ST regions of MPTP mice brain showed a significant up-
regulation of iNOS expression [F (4,10) = 112.2, p<0.01 and F (4,10) 
= 73.47, p<0.01, respectively] when compared to the vehicle treated 
mice. TEL (3 and 10 mg/kg) significantly ameliorated these changes 
(p<0.01) in both the regions (fig. 1).  
 
Fig. 1: Effect of TEL on iNOS mRNA expression in MPTP intoxicated 
mice brain. Values were expressed in mean±SEM, n=3 
animals/group, statistical analysis was performed using one way 
ANOVA followed by Tukey’s multiple comparison test, ## indicates p 
value<0.01 Vs group I, ** indicates p value<0.01 Vs group II 
 
TEL decreased NO levels and increased GSH content in MPTP 
intoxicated mice brain 
A significant increase in NO levels [F (4,10) = 97.15, p<0.01 and F 
(4,10) = 22.27, p<0.01, respectively] and decrease in GSH content [F 
(4,10) = 34.96, p<0.01 and F (4,10) = 64.00, p<0.01, respectively] 
were observed in SNpc and ST regions of MPTP mice when 
compared to vehicle treated mice. Oral administration of TEL (3 and 
10 mg/kg) significantly decreased NO levels (p<0.05 and 0.01; 
p<0.01, respectively) and increased GSH content (p<0.01; p<0.05 
and 0.01, respectively) in SNpc and ST regions when compared to 
MPTP mice (fig. 2). 
TEL increased the nissl staining in MPTP intoxicated mice brain 
SNpc and ST regions of MPTP mice brain showed a significant 
decrease in % nissl positive cells [F (4,10) = 159.8, p<0.01 and F 
(4,10) = 92.68, p<0.01, respectively] when compared to the vehicle 
treated mice. TEL (3 and 10 mg/kg) significantly (p<0.01) increased 
% nissl positive cells in both the regions, as compared to MPTP 
intoxicated mice (fig. 3). 
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Fig. 2: Effect of TEL on nitrite and GSH levels in MPTP 
intoxicated mice brain. Values were expressed in mean±SEM, 
n=3 animals/group, statistical analysis was performed using 
one way ANOVA followed by Tukey’s multiple comparison test, 
## indicates p value<0.01 Vs group I, *,** indicates p value<0.05 
and 0.01, respectively Vs group II. 
 
TEL increased NeuN expressions in MPTP intoxicated mice 
brain 
SNpc and ST regions of MPTP mice brain showed a significant 
decrease in % NeuN immunopositive cells [F (4,10) = 274.1, p<0.01 
and F (4,10) = 86.24, p<0.01, respectively] when compared to the 
vehicle treated mice. TEL (3 and 10 mg/kg) significantly (p<0.01) 
increased % NeuN immunopositive cells in both the regions in 
comparison to MPTP mice (fig. 4). 
DISCUSSION 
Since the discovery of RAS in brain, several studies focused on the 
role of RAS modulators in the management of PD [24]. In the present 
study, TEL decreased iNOS expression and NO levels and increased 
GSH content which could be the, or at least in part, for the increased 
neuronal survival in MPTP intoxicated mice brains. This shows that 
TEL might play a vital function in the management of PD through the 
regulation of nitrosative stress and inflammatory pathway. 
Increased levels of inflammatory mediators such as tumor necrosis 
factor alpha (TNFα), interleukin (IL)-1β and iNOS, along with activated 
microglia and astrocytes were observed in PD brain [25, 26]. Activation 
of microglia and inflammatory cytokines in SNPc and ST regions was also 
reported in acute MPTP mice model of PD [27]. The present study 
demonstrated the decreased iNOS expression in TEL administration, 
which may be through the regulation of these inflammatory processes. 
It has been revealed that increased NO release, produced by iNOS 
was observed along with the inflammatory mediators [28]. NO in 
turn involved in mitochondrial electron transport chain dysfunction 
resulting in the over production of ROS [29]. NO also easily binds 
with superoxide anion (O2•) as well and forms a strong oxidant, 
peroxynitrite (ONOO•) which ultimately involves in the nitration of 
proteins, mainly in tyrosine residues,  
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Fig. 3: Effect of TEL on % nissl positive cells in MPTP intoxicated mice brain. Pictures represent nissl positive cells of (A) SNPc and (B) ST 
brain regions X 400 magnification. (1) Normal control, (2) MPTP induced mice brain, (3) TEL (3 mg/kg b. wt.) administered MPTP mice 
brain, (4) TEL (10 mg/kg b. wt.) administered MPTP mice brain and (5) TEL (10 mg/kg b. wt.) administered normal mice brain. (C) Values 
were expressed in mean±SEM, n=4 animals/group, statistical analysis was performed using one way ANOVA followed by Tukey’s multiple 
comparison test, ## indicates p value<0.01 Vs group I, ** indicates p value<0.01 Vs group II 
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lipid oxidation, DNA strand breaks and leading to nitosative stress 
induced cell death [30, 31]. On the other hand, Clementi et al. [32] 
showed that persistent inhibition of mitochondrial respiration by NO 
results in the depletion of GSH in SNPc and ST brain regions. In the 
current study, decreased NO and increased GSH levels in TEL 
administration may be through its anti-oxidant effect in MPTP 
intoxicated mice brain. In addition, TEL has the potency to improve 
NeuN expression and restores the neurons from nuclear 
pigmentation and cytoplasmic vacuolation in SNPc and ST brain 
regions of MPTP mice brain. These data demonstrates the apparent 
role of TEL, AT1R antagonist, in regulating the inflammatory and 
oxidative stress in PD. 
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Fig. 4: Effect of TEL on % NeuN immunopositive cells in MPTP intoxicated mice brain. Pictures represent NeuN immunopositive cells of 
(A) SNPc and (B) ST brain regions X 400 magnification. (1) Normal control, (2) MPTP induced mice brain, (3) TEL (3 mg/kg b. wt.) 
administered MPTP mice brain, (4) TEL (10 mg/kg b. wt.) administered MPTP mice brain and (5) TEL (10 mg/kg b. wt.) administered 
normal mice brain. (C) Values were expressed in mean±SEM, n=4 animals/group, statistical analysis was performed using one way 
ANOVA followed by Tukey’s multiple comparison test, ## indicates p value<0.01 Vs group I, ** indicates p value<0.01 Vs group II 
 
CONCLUSION 
In conclusion, the present study reveals the neuroprotective effect of 
TEL against MPTP induced nitrosative stress and neurodegeneration 
in C57BL/6J mice. This study adds support to its restoring effect in 
acute conditions and it may be consider for clinical trials in PD. 
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Abbreviation 
TEL–Telmisaratan; AT1R-Angiotensin type 1 receptor; MPTP-1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD-Parkinson’s disease; 
iNOS-Inducible nitric oxide synthase; NO-Nitric oxide; GSH-Reduced 
glutathione; SNPc-substantial nigra; ST–striatum; NeuN-Neuronal 
nuclei; ROS-Reactive oxygen species; RAS-Renin angiotensin system; 
CMC-Carboxy methyl cellulose; IAEC-Institutional Animal Ethics 
Committee; RT-PCR-Reverse Transcriptase–Polymerase chain 
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